Clinical Trial Update: This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated [Phase 1]

View source ↗

Summary

A phase 1 international study assesses three doses of BI 690517 in patients with diabetic nephropathy to evaluate how the drug is absorbed and tolerated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• BI 690517

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetic Nephropathies | Phase 1 | Status: COMPLETED